Start from what you want to change.

BPC-157 and TB-500 are the two peptides most associated with soft-tissue recovery, and the two most often bought from unregulated websites. In animal studies both have been reported to speed healing of tendon, ligament and muscle injuries. In humans, BPC-157 has no completed randomised trial, and TB-500's human data comes mainly from trials of a related thymosin beta-4 product for the eye, not for sports injury.

That gap is why we describe the evidence as limited, and why a clinician rather than a forum decides whether a program is appropriate. Under the HHS policy each is prepared as a single-ingredient product: the "Wolverine stack" of both in one vial is not something a compliant pharmacy will make, though a clinician may prescribe each separately where appropriate.

BPC-157 is modelled on a protective protein in human gastric juice, and its earliest research was on the stomach lining. KPV, a three-amino-acid fragment of a natural hormone, has been studied in animal models of inflammatory bowel disease, where it is taken up by gut cells and dampens inflammatory signalling.

Both are permitted by mouth under the policy (BPC-157 only where the pharmacy can document that the specific oral formulation is absorbed in humans). A persistent gut problem needs a diagnosis first; a clinician will not prescribe a peptide in place of one.

KPV has been studied in cell and animal models of skin inflammation and wound healing, where it reduces the signals that drive redness and swelling. The policy allows it as a topical and oral product, not an injection. BPC-157 topical is also on the permitted list.

Note what is not here: GHK-Cu, the copper peptide popular for skin and hair, is not one of the six. Its topical cosmetic forms are widely sold as skincare, and FDA has said non-injectable routes would return to Category 1, but injectable GHK-Cu is not compoundable today. We say so rather than selling around it.

Epitalon is a four-amino-acid peptide from decades of Russian research on the pineal gland. The research record covers melatonin production, sleep patterns and telomerase activity in cells, and long-term observational studies in older adults. The policy limits it to intermittent courses with breaks, which matches how it was studied.

It is the peptide most often sold to the longevity audience, and the one where the gap between the marketing and the controlled human evidence is widest. A program here is a course, not a continuous subscription.

Semax is a synthetic fragment of a pituitary hormone, registered as a nasal medicine in Russia since 1996 for stroke and cognitive disorders. Of the six, it has the largest human record, several hundred subjects in published intranasal studies, which the policy cites as reporting no adverse outcomes. Intranasal is the only route a pharmacy may prepare; injectable Semax falls outside the policy.

The research is on clinical populations, not healthy adults looking for an edge, and that is how a clinician will read it.

MOTS-c was discovered in 2015, encoded in mitochondrial DNA. In mice it has been reported to improve insulin sensitivity and running capacity, and human studies so far are observational: levels fall with age and rise with exercise. It is injected, subcutaneously or intramuscularly, under the policy.

If weight loss is the goal, the honest answer is that MOTS-c is not a weight-loss drug and no compounded peptide on this site is. Approved GLP-1 medicines exist for that and belong with your own doctor.